Trial record 20 of 233 for:
asthma [CONDITION] AND child [AGE-GROUP] | Open Studies
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by MetroHealth Medical Center.
Recruitment status was Recruiting
Information provided by:
MetroHealth Medical Center
First received: November 18, 2009
Last updated: May 24, 2011
Last verified: November 2009
The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.
||Observational Model: Case Control
Time Perspective: Prospective
||β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma
Primary Outcome Measures:
- B2AR polymorphisms associated with albuterol responsiveness in acute asthma. [ Time Frame: ~ 1 hour following 3 doses of albuterol Q 20 min ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
- B2AR haplotypes [ Time Frame: ~ 1hr post 3 doses of albuterol ] [ Designated as safety issue: No ]
DNA for analysis of B2AR polymorphysims, DNA for genes for inflamation,steroid and leukotriene responsiveness.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2012 (Final data collection date for primary outcome measure)
Those who respond clinically to albuterol.
Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
|Ages Eligible for Study:
||16 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Asthmatic who presented to an Emergency Room with acute symptomatic airway obstruction who are treated with standard doses of albuterol and who either terminate their attacks rapidly or who are admitted to hospital for extensive treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016444
|MetroHealth Medical Center
|Cleveland, Ohio, United States, 44109 |
|Contact: Robynn Cox, RN 216-778-3227 email@example.com |
|Contact: Cynthia Newman, RN 216-778-3237 firstname.lastname@example.org |
|Principal Investigator: E. R. Mc Fadden, Jr, MD, |
MetroHealth Medical Center
No publications provided
||E. R. Mc Fadden, Jr., MD, DSc, MetroHealth Medical Center, Case Western Reserve University School of Medicine
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 18, 2009
||May 24, 2011
||United States: Institutional Review Board
Keywords provided by MetroHealth Medical Center:
Acute asthma responsive and unresponsive to albuterol
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 22, 2014
Immune System Diseases
Lung Diseases, Obstructive
Respiratory Tract Diseases
Adrenergic beta-2 Receptor Agonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents